The Role of glypican-1 in Pancreatic Cancer Development and Progression

磷脂酰肌醇蛋白聚糖-1 (glypican-1) 在胰腺癌发生和进展中的作用

基本信息

  • 批准号:
    8391104
  • 负责人:
  • 金额:
    $ 6.38万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-12-01 至 2013-11-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic and biologically aggressive malignancy that causes approximately 34,000 deaths in the United States each year. PDAC harbors several molecular alterations including activating KRAS mutations, homozygous deletion of the tumor suppressor gene p16INK4A/p14ARF, and overexpression of heparin binding growth factors and their receptors. In addition, glypican-1 (GPC1), a cell-surface heparan sulfate proteoglycan (HSPG) is released by cancer cells, expressed by fibroblasts, and is over-expressed in PDAC. GPC1 enhances the signaling pathways activated by several heparin binding growth factors (HBGFs), especially fibroblast growth factors (FGFs), heparin binding EGF like growth factor (HB-EGF), and heregulins. These HBGFs play critical roles in cell growth, differentiation, adhesion, transformation and metastasis. Additionally, suppression of GPC1 abrogates mitogenic signaling in response to HBGFs in vitro and attenuates tumor growth and metastasis in vivo. These data indicate that GPC1 is not only overexpressed in PDAC but also that host-derived and cancer cell-derived GPC1 contribute to enhanced tumor growth, angiogenesis, and metastasis. Therefore, three specific aims are proposed to test the hypothesis that GPC1 plays a pivotal role in PDAC progression and metastasis by enhancing oncogenic signaling pathways both in the tumor and within the tumor associated stroma. First, tumors and primary cancer cell lines isolated from the novel transgenic mouse model: Pdx-1-Cre; LSL-KrasG12D; INK4ALox/Lox; GPC1+/+ orGPCI -/-will be fully characterized through a series of mechanistic in-vitro assays desined to assess the impact of GPC1 on proliferation, migration, and invasion. Next, in order to delineate the structural components critical for GPC1 signaling functions, primary cancer cell lines that overexpress modified versions of GPC1 will be studied both in vitro and in an orthotopic syngeneic mouse model. Lastly, two transgenic mouse models will be created, one that overexpresses GPC1 alone and another that overexpresses GPC1 in conjunction with activated KrasG12D. These mouse models will be used to determine GPC1 contribution to the initiation and/or progression of pancreatic adenocarcinomas. This research will not only significantly enhance our understanding of how GPC1 functions, especially what regions are critical for its activity, but it will also assess the importance of GPC1 in tumor development and progression in pancreatic cancer. These data may provide support for the efficacy of targeting GPC1 either alone or in combination with other therapeutic targets.
描述(由申请人提供):胰腺导管腺癌(PDAC)是一种高度转移性和生物侵袭性恶性肿瘤,每年在美国造成约34,000例死亡。PDAC具有几种分子改变,包括激活KRAS突变、肿瘤抑制基因p16 INK 4A/p14 ARF的纯合缺失以及肝素结合生长因子及其受体的过表达。此外,磷脂酰肌醇蛋白聚糖-1(GPC 1)是一种细胞表面硫酸乙酰肝素蛋白聚糖(HSPG),由癌细胞释放,由成纤维细胞表达,并在PDAC中过表达。GPC 1增强由几种肝素结合生长因子(HBGF),特别是成纤维细胞生长因子(FGF)、肝素结合EGF样生长因子(HB-EGF)和heregulins激活的信号传导途径。这些HBGF在细胞生长、分化、粘附、转化和转移中起关键作用。此外,GPC 1的抑制在体外消除了响应于HBGF的促有丝分裂信号传导,并在体内减弱了肿瘤生长和转移。这些数据表明,GPC 1不仅在PDAC中过表达,而且宿主来源和癌细胞来源的GPC 1有助于增强肿瘤生长、血管生成和转移。因此,提出了三个具体的目标来检验GPC 1通过增强肿瘤和肿瘤相关基质中的致癌信号传导途径在PDAC进展和转移中起关键作用的假设。首先,将通过一系列旨在评估GPC 1对增殖、迁移和侵袭的影响的机制性体外测定来充分表征从新型转基因小鼠模型Pdx-1-Cre、LSL-KrasG 12 D、INK 4ALox/Lox、GPC 1 +/+或GPCI-/-中分离的肿瘤和原代癌细胞系。接下来,为了描述对GPC 1信号传导功能至关重要的结构组分,将在体外和原位同基因小鼠模型中研究过表达GPC 1的修饰形式的原代癌细胞系。最后,将创建两种转基因小鼠模型,一种是单独过表达GPC 1,另一种是过表达GPC 1与激活的KrasG 12 D结合。这些小鼠模型将用于确定GPC 1对胰腺癌的起始和/或进展的贡献。这项研究不仅将大大提高我们对GPC 1功能的理解,特别是哪些区域对其活性至关重要,而且还将评估GPC 1在胰腺癌肿瘤发展和进展中的重要性。这些数据可以为单独靶向GPC 1或与其他治疗靶点组合靶向GPC 1的功效提供支持。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Chery Angel Whipple其他文献

Chery Angel Whipple的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Chery Angel Whipple', 18)}}的其他基金

The Role of glypican-1 in Pancreatic Cancer Development and Progression
磷脂酰肌醇蛋白聚糖-1 (glypican-1) 在胰腺癌发生和进展中的作用
  • 批准号:
    7807715
  • 财政年份:
    2010
  • 资助金额:
    $ 6.38万
  • 项目类别:
The Role of glypican-1 in Pancreatic Cancer Development and Progression
磷脂酰肌醇蛋白聚糖-1 (glypican-1) 在胰腺癌发生和进展中的作用
  • 批准号:
    8206875
  • 财政年份:
    2010
  • 资助金额:
    $ 6.38万
  • 项目类别:

相似海外基金

A platform for rapidly generating live attenuated enterovirus vaccines
快速生成减毒肠道病毒活疫苗的平台
  • 批准号:
    24K02286
  • 财政年份:
    2024
  • 资助金额:
    $ 6.38万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
I-Corps: Translation potential of an efficient method to generate live-attenuated and replication-defective DNA viruses for vaccine development
I-Corps:一种有效方法的转化潜力,可生成用于疫苗开发的减毒活病毒和复制缺陷型 DNA 病毒
  • 批准号:
    2420924
  • 财政年份:
    2024
  • 资助金额:
    $ 6.38万
  • 项目类别:
    Standard Grant
Developing a robust native extracellular matrix to improve islet function with attenuated immunogenicity for transplantation
开发强大的天然细胞外基质,以改善胰岛功能,并减弱移植的免疫原性
  • 批准号:
    10596047
  • 财政年份:
    2023
  • 资助金额:
    $ 6.38万
  • 项目类别:
Live attenuated non-transmissible (LANT) Klebsiella pneumoniae vaccines
肺炎克雷伯氏菌减毒非传染性 (LANT) 活疫苗
  • 批准号:
    10742028
  • 财政年份:
    2023
  • 资助金额:
    $ 6.38万
  • 项目类别:
Protecting Pigs From Enzootic Pneumonia: Rational Design Of Safe Attenuated Vaccines.
保护猪免受地方性肺炎:安全减毒疫苗的合理设计。
  • 批准号:
    BB/X017540/1
  • 财政年份:
    2023
  • 资助金额:
    $ 6.38万
  • 项目类别:
    Research Grant
A “Goldilocks” live attenuated poultry vaccine for Infectious Coryza
用于传染性鼻炎的“Goldilocks”家禽减毒活疫苗
  • 批准号:
    LP210301365
  • 财政年份:
    2023
  • 资助金额:
    $ 6.38万
  • 项目类别:
    Linkage Projects
A novel live-attenuated Zika vaccine with a modified 5'UTR
一种带有改良 5UTR 的新型寨卡减毒活疫苗
  • 批准号:
    10730832
  • 财政年份:
    2023
  • 资助金额:
    $ 6.38万
  • 项目类别:
Combating melanoma with an attenuated bacterial therapeutic
用减毒细菌疗法对抗黑色素瘤
  • 批准号:
    10659841
  • 财政年份:
    2023
  • 资助金额:
    $ 6.38万
  • 项目类别:
Investigating Host and Viral Factors for Improved Design of Future Live Attenuated Vaccines for IBV
研究宿主和病毒因素以改进未来 IBV 减毒活疫苗的设计
  • 批准号:
    BB/V016067/1
  • 财政年份:
    2022
  • 资助金额:
    $ 6.38万
  • 项目类别:
    Research Grant
L2M NSERC-Bioengineering attenuated Sclerotinia sclerotiorum strains as bioherbicide for cereal production and lawn management
L2M NSERC-生物工程减毒核盘菌菌株作为谷物生产和草坪管理的生物除草剂
  • 批准号:
    576545-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 6.38万
  • 项目类别:
    Idea to Innovation
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了